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Abstract
It is agreed among biostatisticians that prediction models for binary outcomes should satisfy two
essential criteria: First, a prediction model should have a high discriminatory power, implying that
it is able to clearly separate cases from controls. Second, the model should be well calibrated,
meaning that the predicted risks should closely agree with the relative frequencies observed in
the data. The focus of this work is on the predictiveness curve, which has been proposed by
Huang et al. (Biometrics 63, 2007) as a graphical tool to assess the aforementioned criteria. By
conducting a detailed analysis of its properties, we review the role of the predictiveness curve in
the performance assessment of biomedical prediction models. In particular, we demonstrate that
marker comparisons should not be based solely on the predictiveness curve, as it is not possible to
consistently visualize the added predictive value of a new marker by comparing the predictiveness
curves obtained from competing models. Based on our analysis, we propose the “residual-based
predictiveness curve” (RBP curve), which addresses the aforementionened issue and which extends
the original method to settings where the evaluation of a prediction model on independent test
data is of particular interest. Similar to the predictiveness curve, the RBP curve reflects both the
calibration and the discriminatory power of a prediction model. In addition, the curve can be
conveniently used to conduct valid performance checks and marker comparisons.
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The development of prediction models for binary outcomes is an important issue in biomedical research
(Moons et al., 2009). Regarding the development of statistical methodology, key issues are not only
to develop methods for deriving new marker combinations, which usually combine statistical mod-
elling techniques with feature selection, but also to develop reliable methods to evaluate and assess the
practical value of new prediction models.
In the literature it is commonly agreed that prediction models for a binary outcome D should satisfy
two major criteria: First, they should have a high discriminatory power, meaning that they are able to
separate the categories of the binary outcome. For example, prediction models should be able to well
separate cases (D = 1) from controls (D = 0) in case-control studies. Second, they should be well
calibrated, meaning that the predicted risks should closely agree with the relative frequencies observed
in the data. Discrimination and calibration can be evaluated by several measures, such as the area under
the curve (AUC), the Brier score, and the Hosmer-Lemeshow statistic (Hilden & Gerds, 2014; Crowson
et al., 2014).
The focus of this paper is on the predictiveness curve, which was first proposed by Huang, Pepe
& Feng (2007) and has since been used by many authors as a graphical tool to visualize and evaluate
calibration and discriminatory power (Pepe et al., 2008b; Gu & Pepe, 2009; Huang & Pepe, 2009b;
Pepe, Gu & Morris, 2010; Moons et al., 2012; Steyerberg et al., 2014). The predictiveness curve depicts
the risk distribution of a marker (or a marker combination) and is formally defined as follows: Let F
be the cumulative distribution function (cdf) of the marker Y , and let ν = F(Y) ∈ (0, 1) be the ν-th
percentile of Y . Then the risk at a specific value ν is given by
R(ν) = risk(F−1(ν)) = P(D = 1 |Y = F−1(ν)), (1)
and the predictiveness curve is obtained by plotting R(ν) versus ν. When R(·) is not known and es-
timation of the risk is required, for example, by using logistic regression, the predictiveness curve is
obtained by plotting the predicted risk R̂(ν) = r̂isk(F̂−1(ν)) vs. ν = F̂(η), which is equivalent to plotting
r̂isk(η) versus F̂(η), where F̂ is, for example, the empirical cdf and η is an observed value of the marker
Y (see also Gu & Pepe, 2009). In other words, the curve plots the ordered predicted risks (based on
the ordered observed values η of the marker Y) versus the cumulative percentage of individuals with
marker values smaller than or equal to η.
As an example, Figure 1 shows the predictiveness curve for a simulated data set of size n = 10000.
The estimated prevalence in this data set is θ̂ = 1n
∑n
i=1 Di = 0.3, where Di denotes the binary outcome of
observation i. That is, the simulated data contain 30% cases and 70% controls. The values of the marker
combination Y (simulated as the combination of five independent normally distributed markers) range
from −24.5 to 22.3. The dashed gray curve represents the predictiveness curve that was obtained from
fitting a logistic regression model to the data. It can be easily seen from Figure 1 that the predictiveness
curve characterizes the distribution of the risk. Each horizontal line at R̂(ν) = t intersects the curve at
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Interpretation: 75 % of the population have a risk less than or equal to 66 %
−24.5 −1.4 −0.4 0.4 1.4 22.3
Y
θ̂=0.3
Figure 1: Predictiveness curve obtained from the simulated data set of Section 1 with estimated preva-
lence θ̂ = 0.3. The dashed gray line represents the predictiveness curve of a logistic regression
model while the solid black line corresponds to the optimal predictiveness curve that was ob-
tained by using the binary outcome values.
a specific abscissa ν, where ν = R̂−1(t) is interpreted as the proportion of the population that has a risk
of being a case less than or equal to t. Since the predicted risks should be as close as possible to 1 for
cases and 0 for controls, the “optimal” predictiveness curve is a step function that jumps up from 0 to
1 at ν = 1 − θ̂, where θ̂ is an estimate of the prevalence θ = P(D = 1).
Under the assumption that the underlying prediction model is well calibrated, Huang et al. (2007)
suggested interpreting the predictiveness curve as follows: Because a steep slope of the curve indi-
cates that cases and controls are well separated, models with a predictiveness curve that is close to the
“optimal” curve in Figure 1 should have a high discriminatory power. Consequently, the “optimal”
prediction model is attained when the resulting predictiveness curve is equal to the step function in
Figure 1. Based on this interpretation, Pepe et al. (2008b) suggested investigating the performance of
prediction models by comparing their predictiveness curves. This strategy was adopted by Pencina,
D’Agostino & Vasan (2010) and Moons et al. (2012), who assessed the predictive capacity of a new
marker by comparing the resulting predictiveness curves with and without the new marker. In particu-
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lar, Pencina et al. (2010) noticed that in their data the predictiveness curves with and without the new
marker hardly differed. Specifically, the authors pointed out that there is a need in future research to
explore whether this is “caused by the inadequacy of the markers under consideration, or if it is an
inherent property of the predictiveness curve itself” (Pencina et al., 2010, p. 6).
In this paper, we carry out a detailed analysis of the properties of the predictiveness curve and review
its role in the performance assessment of biomedical prediction models. A key result of our analysis
is that the predictiveness curve should not be used as a criterion for marker comparison unless one
has made sure that all prediction models under consideration are well calibrated. In particular, the
predictiveness curve does not necessarily provide information on the added predictive value of a new
marker, a result that is in line with the observation of Pencina et al. (2010). The main reason for
these problems is contained in the definition of the predictiveness curve itself: From Equation (1), it
is obvious that the curve is solely based on the distribution of the marker Y but not on the observed
values of the binary outcome D in the data. Consequently, the predictiveness curve alone does not
reveal whether a model fits the data well, and it is possible to derive inferior prediction models that
nevertheless result in the “optimal” predictiveness curve of Figure 1. Examples are given in Section 6.
Because it has been recognized that the predictiveness curve does not adequately measure calibration
(Cook, 2010), several authors have suggested first checking whether all prediction models under con-
sideration are well calibrated (Cook, 2010; Pepe et al., 2013). This could be done, for example, with
the help of goodness-of-fit tests such as the Hosmer-Lemeshow test (Pepe et al., 2008b; Pepe, 2010).
In the next step, predictive performance would be based on a comparison of the slopes of the resulting
predictiveness curves. Although this approach solves part of the problem, it does not overcome the
original shortcomings in the definition of the predictiveness curve. In particular, we will demonstrate
in Section 6 that the Hosmer-Lemeshow test is not sensitive enough to reliably separate well calibrated
from badly calibrated models (see also Peek et al., 2007; Cook, 2010). Consequently, artefacts are still
possible, and it is unclear how one should compare markers via their predictiveness curves in these
situations.
To overcome these problems, we propose a new graphical tool, the residual-based predictiveness
curve (hereinafter abbreviated as RBP curve), which does not depend on the results of previously con-
ducted calibration checks. The idea is to incorporate the binary outcome values into the definition of
the predictiveness curve itself, thereby defining a new evaluation criterion for marker performance that
also reveals how well a model is calibrated. The properties of this RBP curve will be assessed in detail
in Section 5, and it will be demonstrated that it can address the aforementioned problems. Specifically,
it is possible to obtain valid performance assessments via graphical checks of the RBP curve. Also, sev-
eral well-known performance criteria, such as the true positive rate (TPR), the false positive rate (FPR)
and the proportion of explained variation (PEV) (see Sachs & Zhou, 2013) can be derived graphically
from the RBP curve.
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2 Notation and Definitions
In the biomedical sciences, binary outcomes often refer to the status of a disease, with diseased (D = 1)
and healthy (D = 0) subjects being considered cases and controls, respectively. Unless otherwise
stated, these terms will be used synonymously in the rest of this paper. To predict the disease status D,
we will consider a continuous marker (or marker combination) that will be denoted by Y . The observed
value of Y will be denoted by η. The risk of being diseased given a particular value of Y will be defined
as risk(η) := P(D = 1 |Y = η). Generally, there are two possibilities to obtain predictions for D:
The first possibility is to use a single marker Y , for example the total prostate specific antigen (PSA)
to detect prostate cancer or the CA-125 antigen to detect ovarian cancer. The second possibility is to
define Y as a score, which is often constructed as a linear combination of single markers. Scores for
the early detection of prostate cancer can, for example, be defined by combinations of PSA and other
blood-based markers (see Pepe et al., 2008b; Shariat et al., 2011). The values of the score are usually
derived by fitting a prediction model to a data set D = {(xi,Di), i = 1, . . . , n}, where Di denotes the
disease status of subject i and xi = (1, xi,1, . . . , xi,P)> is the associated vector of P marker values that
may include the constant 1 for the intercept term. The score values are often assumed to be a linear
combination of the marker values, i.e. ηi = x>i β, i = 1, . . . , n, where β is a vector of coefficients that
has to be estimated. Typically, a prediction model is obtained by modelling the risk
risk(ηi) = P(Di = 1 |Yi = ηi) = G(x>i β), i = 1, . . . , n, (2)
using a parametric function G that transforms the range of the score to the unit interval (0, 1). This
parametrization is widely used in parametric modelling, where in general G has the form of a cu-
mulative distribution function (cdf). For example, in logistic regression, G is the logistic distribution
function, and the risk is given by
risk(ηi) = P(Di = 1 |Yi = ηi) =
exp(x>i β)
1 + exp(x>i β)
.
3 Calibration and Discrimination
In the literature, a large variety of approaches have been suggested to measure the predictive capacity
of a marker Y (see Pepe et al., 2008b; Steyerberg et al., 2010). Among the most important principles
are calibration and discrimination. Generally, a well calibrated prediction model is achieved when,
for appropriate groupings of the observations, the predicted risks closely agree with the proportion of
diseased in each group. An appropriate grouping, which we will consider, is grouping the observations
via quantiles of the predicted risks. A well discriminating model is able to separate cases from controls,
i.e., when both sensitivity (the proportion of diseased subjects that are correctly identified as having the
disease) and specificity (the proportion of healthy subjects that are correctly identified as not having
the disease) are high. While both concepts, calibration and discrimination, are well-established quality
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criteria for markers in biomedical research, an important issue is how to quantify them, i.e., how to
define appropriate measures for evaluating calibration and discrimination. In this respect, Huang et al.
(2007) and Pepe et al. (2008b) have shown that many relevant properties of a marker can be summarized
through the predictiveness curve.
3.1 Measures of Calibration
Pepe et al. (2013) distinguish between good calibration of a model and a well calibrated model. A
measure for good calibration is given by the mean calibration, which is also known as calibration-in-
the-large and measures how well the average risk (over all observations) agrees with the proportion
of diseased subjects. In other words, good calibration is satisfied when the mean predicted risk, i.e.
E(risk(Y)) = 1n
∑n
i=1 r̂isk(ηi), is close to the estimated prevalence θ̂. Interestingly, the calibration-in-the-
large is equal to the area under the predictiveness curve, which should therefore be as close as possible
to θ̂ to ensure good calibration (Huang & Pepe, 2009b). In the case of the “optimal” predictiveness
curve, for example, the area under the curve is simply the area of a rectangle with width θ̂ and height 1.
Although the calibration-in-the-large is a valuable tool for calibration assessment, Cook (2010)
pointed out that evaluating this measure is not sufficient to fully assess the calibration of a predic-
tion model. This is because the predicted risks of a well calibrated model should also be close to the
proportions of diseased individuals when the observations are grouped and only a subset of observa-
tions is considered. Therefore, a measure for a well calibrated model can be obtained by grouping
the observations via quantiles of the predicted risks and comparing the mean of the predicted risk in
each group with the respective proportion of diseased within each group. This strategy gives rise to
the Hosmer-Lemeshow statistic (see Crowson et al., 2014). Pepe et al. (2008b) suggested visualizing
the components of the Hosmer-Lemeshow statistic by additionally plotting the observed proportions of
diseased at the midpoint of each decile of the predicted risks (see Figure 2). If the points are close to
the predictiveness curve, the prediction model in question is likely to be well calibrated.
3.2 Measures of Discrimination
A well discriminating model is obtained when the prediction model is able to separate cases from
controls, i.e., when both the sensitivity (the proportion of diseased subjects that are correctly identified
as having the disease) and the specificity (the proportion of healthy subjects that are correctly identified
as not having the disease) are high. The discriminatory power of a well calibrated prediction model can
be visually assessed by inspecting the slope of the predictiveness curve. Because the observations with
higher risks are located to the right side of the vertical line at ν = 1 − θ̂, a well discriminating model
should assign risk values close to 1 to these observations. Conversely, it should assign risk values
close to 0 to the observations to the left side (i.e., if ν < 1 − θ̂). A well discriminating model should
therefore result in a predictiveness curve with steep slope (see also Huang et al., 2007; Huang & Pepe,
2009a; Moons et al., 2012). In Figure 2, for example, the step function that represents the “optimal”
predictiveness curve jumps from zero to one at 1 − θ̂ = 0.7. This implies that the step function has the
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area under the "optimal" predictiveness curve
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Figure 2: Predictiveness curves obtained from the simulated data set of Section 1. The dashed gray
curve was obtained from a logistic regression model, whereas the step function corresponds
to the optimal predictiveness curve that was obtained from the binary outcome values. The
black points correspond to the proportion of diseased within each decile of predicted risks.
Because the data were generated with the help of a logistic regression model, the black points
are close to the respective predictiveness curve. This indicates that the logistic regression
model is well calibrated.
steepest possible slope and therefore the maximum possible discriminatory power.
A popular measure to quantify the discriminatory power of a prediction model is the proportion of
explained variation (PEV), which can be shown to be equivalent to PEV := E(risk(Y) |D = 1)−
E(risk(Y) |D = 0) (see Pepe et al., 2008a). The PEV measure is the difference between the condi-
tional expectation of risk(Y) in the diseased group and the respective expectation in the healthy group
(Pepe et al., 2008a). Because the first expectation should be close to 1 and the second one close to 0
in a well discriminating prediction model, the PEV is directly related to the slope of the predictiveness
curve. The steeper the slope, the better the population is separated into two groups. If, at the same time,
the model is well calibrated, a steep slope of the curve implies a large value of PEV. Generally, PEV
ranges from 0 (implying minimum possible discrimination) to 1 (implying optimal discrimination).













where G(x>i β) is the parametrization of the risk as in Equation (2) and n j :=
∑n
i=1 I(Di = j), j = 0, 1, is
the number of healthy and diseased subjects, respectively. Our following analysis will be mainly based
on the PEV measure; the relationships of other measures to the predictiveness curve were discussed in
Gu & Pepe (2009).
4 Shortcomings of the Predictiveness Curve
Although the predictiveness curve has proved to be a valuable tool for the characterization of biomarker
combinations, several shortcomings regarding the evaluation of prediction models remain. In particular,
it can be misleading to rely on the predictiveness curve when the aim is to compare different marker
combinations. This problem is mainly due to the fact that the predictiveness curve does not involve
any of the true values of the outcome variable D. Consequently, except for the calibration-in-the-large
(which can be evaluated by inspecting the area under the predictiveness curve), the curve does not
provide any information on how well the prediction models under consideration are calibrated. It is
therefore possible to construct algorithms that “optimize” marker combinations such that they result in
the “optimal” step function shown in Figure 1. In Section 6.2, we will present such an algorithm and
illustrate that the resulting marker combination is impractical and badly calibrated.
The aforementioned problems can also be viewed from a different angle: Recently, Hilden & Gerds
(2014) analyzed the integrated discrimination improvement (IDI) measure and argued that IDI is in-
sufficient for comparing the predictive capacity of two prediction models. The IDI can be defined as
the difference of two PEV values of two prediction models (see Pepe et al., 2008a). Because the PEV
reflects the discriminatory power of a model and does not provide information on whether the model
is well calibrated, the PEV only measures part of the predictive capacity of a marker. As there is a
relationship between PEV and the slope of the predictiveness curve (see Section 3.2), the problems
identified by Hilden & Gerds (2014) naturally apply to the predictiveness curve as well.
Another problem is that the predictiveness curve cannot be used to evaluate whether a prediction
model overfitted the data it was derived from. Evaluating the curve on an external test data set will not
help in this respect, as the predictiveness curve only displays the distribution of risk(Y). Consequently,
if the covariates in the test data follow the same distribution as the covariates in the original data, both
curves will be highly similar regardless of whether the model overfits the original data or not. Again,
this problem arises from the fact that the predictiveness curve does not involve the true outcome status
D that is needed to evaluate prediction accuracy. We will illustrate this issue in detail in Section 6.1.
As noted in Section 1, several authors have suggested conducting marker comparisons only if the
marker combinations under consideration are well calibrated. The current state of the art is therefore to
test whether prediction models are well calibrated and then to compare the predictiveness curves with
respect to their slopes (Pepe et al., 2013). Calibration can, for example, be investigated by the Hosmer-
Lemeshow test (Pepe et al., 2008b; Crowson et al., 2014). Although this strategy solves part of the
problem, wrong conclusions are still possible: Because of power issues of the Hosmer-Lemeshow
test (Peek et al., 2007; Cook, 2010), it is likely that prediction models with very different levels of
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calibration will enter the final slope comparison. Also, the two-step approach automatically discards
models that do not pass the calibration test, which implies that no graphical checks of these models are
provided. Again we will illustrate these issues in detail in Section 6.3.
To address these shortcomings, we propose the residual-based predictiveness (RBP) curve, which is
an improved graphical tool to evaluate and compare the accuracy of prediction models. We will start
with the definition of the RBP curve and then show how various other popular measures of calibration
and discrimination can be derived from it. In Section 6, we will present the results of several simulation
studies that demonstrate how the RBP curve can be used to remedy the shortcomings of the original
curve.
5 The RBP Curve
Instead of plotting R(ν) versus ν or, equivalently risk(Y) versus F(Y) (see Gu & Pepe, 2009), we
propose using the residuals ε = D − risk(Y) and plot ε versus Fε(ε). The index ε in Fε(ε) (the cdf of
the residuals) was introduced to emphasize the difference between Fε(·) and F(·), which is the cdf of
Y . This strategy allows us to directly assess the calibration of a prediction model (without plotting any
additional points) because the real outcome D is included in the definition of the curve. In particular,
considering the residuals ε makes it easier to assess the predictive capacities when comparing RBP
curves. When statistical estimation is involved, we consider the estimated residuals ε̂i = Di − p̂i, where
p̂i := r̂isk(ηi) ∈ [0, 1] and Di ∈ {0, 1}.
To generate Figure 3, we used the simulated data and the predictions from the logistic model de-
scribed in Section 1. The figure shows the RBP curve, and also how different criteria (calibration-in-the-
large, calibration across deciles, PEV, FPR, TPR) can be obtained from the RBP curve. The horizontal
line corresponds to the optimal RBP curve, where all residuals are zero. By definition, all non-diseased
subjects {i : Di = 0} are located below the horizontal zero line, as ε̂i = Di − p̂i = − p̂i ≤ 0. Accordingly,
all diseased subjects {i : Di = 1} are located above the horizontal line, as ε̂i = Di − p̂i = 1− p̂i ≥ 0. The
vertical line that splits diseased and non-diseased subjects is located at 1− θ̂ (one minus the prevalence).
Therefore, we can derive the proportion of diseased from this line (which is θ̂ = 0.3 in Figure 3(a)).
Detailed descriptions of the relation between the RBP curve and several performance measures are
given in the following sections.
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Figure 3: Derivation of performance measures from the RBP curve as described in Section 5. The
numbers in panels (a) and (b) correspond to the areas of the respective regions. The bar plots
in the second figure facilitate the comparison of areas with the same gray tones, which should
be equal in magnitude.
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5.1 Relation to the Calibration-in-the-large
The calibration-in-the-large reflects whether a prediction model satisfies good calibration, meaning
that the expected value of the risk, which can be estimated by 1n
∑n
i=1 p̂i, should be as close as possible
to the prevalence θ = P(D = 1), which is estimated by θ̂ = 1n
∑n
i=1 Di. It follows that the risks should



























Therefore, ÂRBP = 0 ensures good calibration. Here, we prefer using the term integral rather than
area because ÂRBP can also take negative values. When the term area is used, we are referring to the
positive valued integral. Visually, good calibration implies that the area above the horizontal zero line
and the area below the horizontal zero line should be approximately equal, or equivalently, the sum of
both integrals should be as close as possible to zero. This is because the integral below the RBP curve
























where the first sum corresponds to the integral below the horizontal zero line and the second sum
corresponds the integral above the horizontal zero line. For example, in Figure 3(a), the integral below
the horizontal zero line is 1n
∑




i:Di=1(1 − p̂i) = 0.0611.
5.2 Relation to the Calibration across Deciles
In a similar manner to the calibration-in-the-large, the calibration across deciles is visually obtained by
contrasting the area above the horizontal zero line with the area below the horizontal zero line. For the
calibration across deciles, we need to additionally split the integral according to deciles of the predicted
risks. The relationship between the RBP curve and the calibration across deciles can then be derived
as follows: Let Qq = {i : p̂i ∈ (q − 0.1, q)} with q = 0.1, 0.2, . . . , 1, be the sets of observations whose
predicted risks are included in intervals that are bounded by the ((q− 1) ∗ 10)-th and (q ∗ 10)-th deciles,
respectively. For example, Q0.1 = {i : p̂i ∈ (0, 0.1)} is the set of observations whose predicted risks are
below the first decile. Furthermore, let ÂqRBP, q = 0.1, 0.2, . . . , 1, be the integrals that are obtained by
splitting ÂRBP according to deciles of the predicted risk, so that ÂRBP = Â0.1RBP + Â
0.2

















where n0.1 = |Q0.1| is the number of observations below the first decile of predicted risks. Analogously










where the first sum corresponds to the integral below the horizontal zero line (using only the obser-
vations, whose predicted risks are below the first decile, i.e., for i ∈ Q0.1 = {i : p̂i ∈ (0, 0.1)}). The
second sum corresponds to the integral above the horizontal zero line, also using only the observations
i ∈ Q0.1 = {i : p̂i ∈ (0, 0.1)}. When both integrals are equal in magnitude, they sum up to zero, yielding
Â0.1RBP = 0, so that perfect calibration for the first decile is satisfied. A well calibrated prediction model
in terms of the calibration across deciles is given when each integral Â0.1RBP, Â
0.2
RBP, . . . , Â
1
RBP is close to
zero. In Figure 3(b), this is visualized by contrasting areas with the same gray tones, where each area
with the same gray tone contains the predicted risks for a specific decile. In the case of a well cali-
brated prediction model, the areas with the same gray tones above the horizontal zero line and below
the horizontal zero line should be approximately equal.
5.3 Relation to PEV
The PEV measure is visually obtained by the difference of the gray areas in Figure 3(c). By defini-
tion, the gray shaded area above the horizontal line corresponds to the conditional expectation E1 :=
E(risk(Y) |D = 1) in the diseased group (estimated by Ê1 = 1n1
∑
i:Di=1 p̂i), whereas the gray shaded
area below the horizontal line corresponds to the conditional expectation E0 := E(risk(Y) |D = 0) in
the non-diseased group (estimated by Ê0 = 1n0
∑
i:Di=0 p̂i). It follows that the PEV measure, which is
the difference of the two conditional expectations, is estimated by P̂EV = Ê1 − Ê0. For example, in
Figure 3(c) one obtains
P̂EV = Ê1 − Ê0 = 0.796 − 0.087 = 0.709.
5.4 Relation to FPR and TPR
By definition, true and false positive rates are given by
T PR(θ) = P(risk(Y) > θ |D = 1) = P(1 − risk(Y) < 1 − θ |D = 1) = Fε(1 − θ |D = 1)
and
FPR(θ) = P(risk(Y) > θ |D = 0) = P(0 − risk(Y) < 0 − θ |D = 0) = Fε(0 − θ |D = 0),
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respectively. Therefore, estimated values of FPR and TPR are given by the intersection of the RBP
curve with the horizontal lines at 0 − θ̂ and 1 − θ̂, respectively (see Figure 3(d)).
5.5 Distributional Interpretation
As shown in Section 1, the predictiveness curve contains the full distribution of the risk R(ν), which
is depicted as a function of the quantiles of the marker Y . It follows that one can make interpretations
about the proportion of the population having a risk of being diseased less than or equal to a specific
value t (see also Figure 1). Analogous distributional interpretations can be derived from the RBP curve.
This is most easily seen when writing the proportion of the population having a risk of being diseased
less than or equal to t, P(risk(Y) ≤ t), in terms of the TPR, FPR and the prevalence θ, whose values
can all be obtained from the RBP curve:
P(risk(Y) ≤ t) = 1 − P(risk(Y) > t)
= 1 − [P(risk(Y) > t |D = 1) · P(D = 1) + P(risk(Y) > t |D = 0) · {1 − P(D = 1)}]
= 1 − {T PR(t) · θ + FPR(t) · (1 − θ)} .
The values for T PR(t) and FPR(t) are given by the intersection of the curve and the horizontal lines at
1 − t and −t.
In Figure 3(e), for example, we used t = 0.66 and obtained T PR(t) = 0.766 and FPR(t) = 0.029.
Therefore, it follows that P(risk(Y) ≤ t) = 0.75, which yields the same distributional interpretation as
in Figure 1, namely that 75% of the population have a risk less than or equal to 66%.
5.6 Relation to the L1 and L2 Loss
We finally note that there is a direct relationship between the RBP curve and the mean absolute error















As seen from the definition of the residuals εi = Di − p̂i, the RBP curve depicts the signed summands
of the L1 loss in Equation (4). Visually, the MAE reflects the sum of the two positive valued integrals
below and above the RBP curve. For example, in Figure 3(a) the area below the horizontal zero line
(that is, the positive valued integral) is 0.0611, and the area above the horizontal zero line is 0.0611,
yielding MAE = 0.0611+0.0611 = 0.1222. As a consequence, changes in the MAE will automatically
be reflected in changes of the RBP curve, rendering the RBP curve a convenient tool for a detailed
graphical illustration of the MAE.
In addition, there is an indirect relation between the RBP curve and the Brier score, which is based
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By definition, the RBP curve depicts the signed square roots of the summands in Equation (5). There-
fore, changes in the Brier score are also reflected in changes of the RBP curve.
6 Simulations
To illustrate the importance of calibration checks before assessing the predictive capacity of a predic-
tion model, we start with a model that massively overfits the data. By evaluating this model with the
predictiveness curve, we demonstrate that calibration checks are not possible without consideration of
the outcome variable D. Furthermore, we show that it is possible to construct well calibrated predic-
tion models with almost completely overlapping predictiveness curves (suggesting similar predictive
capacities), even in the case in which one of the models ignores an influential marker. In contrast to
the original predictiveness curves, examination of the RBP curves can reveal both overfitting and the
inclusion/exclusion of influential markers.
6.1 Overfitting Issues
An overfitting prediction model, which often occurs when there are too many markers, is able to fit
a specific data set well, but fails in predicting future values of D (implying that the model has a poor
predictive capacity). To construct an overfitting model, we generated a data set D = {(xi,Di), i =
1, . . . , n} with n = 3000 observations and 1000 non-informative markers x>i = (xi,1, . . . , xi,1000)>.
The data were subdivided into a training set L = {(xi,Di), i = 1, . . . , 1800} and a test set T = D \L.
Based on the training data, we estimated a logistic regression model that overfitted the training data.
The model was subsequently evaluated on the test data set. Panels (a) and (b) in Figure 4 show the
predictiveness curves for the predicted risks of the training and test data. In particular, one can see that
the shapes of both predictiveness curves are similar to the respective “optimal” predictiveness curves,
suggesting an optimal predictive capacity of the model. On the other hand, when considering the cal-
ibration points in Figure 4(b) (corresponding to the test data), one sees that the prediction model is
not well calibrated at all and has therefore a poor predictive capacity. One can see that no valid cali-
bration checks are possible without adding the calibration points to the predictiveness curve. Further,
the predictive capacity of a prediction model cannot be adequately assessed without plotting the points
obtained from the test data.
Figure 4(c) shows the RBP curves obtained from the training and test data. As expected, the RBP
curve of the training data is a horizontal line at zero. As it corresponds to a prediction model with
extreme overfitting, it is very similar to the “optimal” RBP curve defined in Section 5. Unlike the
predictiveness curve of the test data (depicted in Figure 4(b)), the RBP curve obtained from the test
14
data does not look optimal at all. By definition, the RBP curve depends on the real outcome values;
hence it can reveal bad calibration and large prediction errors.
























































































Figure 4: Predictiveness curves and RBP curves of the overfitting prediction model considered in Sec-
tion 6.1. The points correspond to the observed proportions of diseased subjects in the risk
deciles.
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6.2 Pathological Optimization of the Predictiveness Curve
Here we demonstrate that it is even possible to optimize the predictiveness curve of a model with low
predictive capacity such that it still looks “optimal”, as defined by Figure 1. This can be achieved by
direct maximization of the empirical PEV measure, which reflects the steepness of the slope of the
predictiveness curve (see Section 3.2).
To ensure that the optimized predictiveness curve results in an adequate calibration-in-the large that
satisfies E(risk(Y)) = θ and hence corresponds to the area under the “optimal” predictiveness curve in










I(Di = 1), (6)
where the first sum is the empirical counterpart of the expected risk and the second sum is an estimate
of the prevalence θ = P(D = 1) based on samples (xi,Di), i = 1, . . . , n. The resulting optimization




















p ≤ t is an additional constraint that penalizes the size of the coefficients to address
convergence issues and to include an optional shrinking effect for the coefficients as in ridge regression
(see Tibshirani, 1996). In Figure 5, we illustrate that this additional constraint is able to control the
steepness of the predictiveness curve.
To illustrate that solving (7) yields an “optimal” looking predictiveness curve for large t (implying
large coefficients), we conducted a simulation study with n = 10000 observations and P = 5 stan-
dard normally distributed markers X1, . . . , X5 ∼ N(0, 1). The disease status D was generated from the
underlying model
logit(P(D = 1 | xi)) = x>i β, (8)
where the (randomly generated) coefficients β = (−2.71,−2.21,−2.59,−2.12,−2.06,−2.95)> were
used. The first coefficient corresponds to the intercept and the others correspond to the influential
markers.
The simulated data D = {(xi,Di), i = 1, . . . , n}, with n = 10000 observations were subdivided into a
training set L = {(xi,Di), i = 1, . . . , 6000}, on which the estimation of the prediction model was based,
and a test set T = D \ L, on which the model was evaluated. The estimated coefficients that resulted
from solving the optimization problem in (7) with three different boundaries for the squared sum of the
coefficients (t = 36, t = 360 and t = 3600) are presented in Table 1. The resulting predictiveness curves
for training and test sets are shown in Figure 5. The predictiveness curve for t = 3600 suggests a well
discriminating prediction model because of its steep slope. At the same time, the area under the curve
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(being close to the area under the “optimal” predictiveness curve) suggests a perfect calibration-in-the-
large. As a consequence, the curve is close to the “optimal” predictiveness curve and suggests a perfect
predictive capacity.
However, as emphasized in Section 3, one should also consider the calibration across deciles using
the Hosmer-Lemeshow test. As noted by Pepe et al. (2008b), the components of the test statistic can
be visualized through the predictiveness curve by additionally plotting the proportions of diseased for
each decile and by comparing these proportions to the predictiveness curve.
Figure 5 suggests that only the prediction model with t = 36 was well calibrated. Obviously, this
confirms that an “optimal” looking predictiveness curve does not necessarily imply a perfect predictive
capacity of the model. Therefore, care must be taken when making comparisons of prediction models
by solely comparing their predictiveness curves.
An improved strategy was proposed by Pepe et al. (2013), who recommended first checking the cali-
bration of the prediction models under consideration (for example by applying the Hosmer-Lemeshow
test) and then comparing the predictiveness curves to the models that passed the calibration tests. While
this strategy addresses part of the problem, we will show in the next section that it can still yield mis-
leading results.
β0 β1 β2 β3 β4 β5
true coefficients -2.71 -2.21 -2.59 -2.12 -2.06 -2.95
t = 36 -2.67 -2.11 -2.66 -2.04 -2.10 -2.97
t = 360 -8.13 -6.57 -8.58 -6.66 -6.68 -9.40
t = 3600 -25.54 -20.43 -27.12 -21.82 -21.02 -29.62
Table 1: Estimated coefficients obtained from the simulation study in Section 6.2. It can be seen that
the regularization parameter t controls the magnitude of the coefficient estimates, thereby de-
termining the steepness of the slope of the resulting predictiveness curve.
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Figure 5: Simulation study of Section 6.2. The predictiveness curves are based on the predicted risks
of the training and test data using different values of the regularization parameter t. As seen
from the black points (which correspond to the proportions of diseased across deciles), only
the model with t = 36 is well calibrated.
6.3 Model Comparisons
In this section we compare two well calibrated prediction models (one model with and the other model
without a new marker) by their predictiveness curves. The aim of our simulation study is to demonstrate
that making conclusions about the predictive capacity by solely using the predictiveness curve can be
misleading – even if the prediction model is well calibrated.
We used the randomly generated coefficients β = (−2.71,−2.21,−2.59,−2.12,−2.06, 1)>, where the
first coefficient corresponds to the intercept and the others correspond to the influential markers, and
simulated 1000 data sets with five markers X1, . . . , X5 ∼ N(0, 1). Each of the 1000 data sets was split
into a training set and a test set (containing 60% and 40% of the observations, respectively). Moreover,
in each of the 1000 simulation runs we fitted one model with marker X5 (model “M1”) and one model
without X5 (model “M0”) by solving the optimization problem in (7). The choice of the boundary t
was based on the coefficients that resulted from a logistic model (denoted by β̂glm). For model M0
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we used t = 1.07 · β̂glm>β̂glm. This strategy resulted in a steeper predictiveness curve than the one
resulting from the logistic model since the coefficients were allowed to be larger. For model M1, we
used t = 0.91 · β̂glm>β̂glm in order to obtain predictiveness curves with flatter slopes. We then applied
the Hosmer-Lemeshow test in order to select those data sets whose predicted risks (for both the training
and the test data) were well calibrated. In our simulation study, 114 out of the 1000 data sets passed
the Hosmer-Lemeshow test. We used these 114 data sets for the following computations.
Figure 6 shows the averaged predictiveness curves obtained from the test data (panel (a)) as well
as the averaged pointwise differences between the predictiveness curves obtained from the 114 test
data sets (panel (c)). Since the curves are almost completely overlapping and the pointwise differences
scatter around the zero line, the predictive capacities indicated by the predictiveness curves are similar
for the two models. It is therefore difficult to tell whether the model with or without X5 performed
better, although, according to the data generating process, the model that includes X5 should have
resulted in a higher predictive capacity.
In contrast to panels (a) and (c), panels (b) and (d) of Figure 6 (which are based on the RBP curve
instead of the predictiveness curve) indicate a difference between models M1 and M0. Specifically,
panel (d) indicates that model M1 has a higher predictive capacity than model M0. This result was
confirmed by the evaluation of various other performance measures on the test data (Figure 7).
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(c) pointwise difference M1 − M0
ν = F̂(Y)
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(d) pointwise difference M1 − M0
F̂ε(ε̂)
Figure 6: Results of the simulation study of Section 6.3. Panels (a) and (c) show the averaged pre-
dictiveness curves for models M0 and M1 and the averaged pointwise differences (with
95% bootstrap confidence bands) between the two predictiveness curves, respectively. Pan-
els (b) and (d) are comparisons of the averaged RBP curves and the averaged pointwise dif-
ferences (with 95% confidence bands), respectively.
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Figure 7: Results of the simulation study in Section 6.3. The box plots show the relative changes of
various performance measures that were evaluated on the 114 test data sets that passed the
Hosmer-Lemeshow calibration test. Note that lower false positive rates (FPR) and lower Brier
scores indicate a better model performance. The respective box plots are therefore below the
horizontal zero line.
7 Evaluation on Real Data
The data set considered in this section was collected by Hatzis et al. (2011). It contains information on
patients with newly diagnosed ERBB2-negative breast cancer and is publicly available from the GEO
repository (http://www.ncbi.nlm.nih.gov/geo). Covariate information is contained in a clinical data set
and a high-throughput molecular data set (omics information). The data are stored in two separate data
sets (GEO accession numbers GSE25055 and GSE25065) that, in our analysis, are merged together and
randomly split into training set and test set containing 2/3 and 1/3 of the observations, respectively.
The response variable considered here is the residual cancer burden (RCB) class. The levels RCB-0
and RCB-I (referring to no and minimal residual disease, respectively) were coded as D = 0, whereas
levels RCB-II and RCB-III (referring to moderate and extensive residual disease, respectively) were
coded as D = 1. Observations with missing values in the clinical data and/or the response (RCB class)
were omitted, yielding training and test sets of sizes 254 and 128, respectively.
To construct a meaningful model that combines clinical and omics information, we used an approach
that was originally proposed by De Bin, Sauerbrei & Boulesteix (2014) (“Strategy 4a”). The main idea
of this strategy is to first fit a model to the omics data and to use the linear predictor obtained from this
model (the so-called omics score) as an additional explanatory variable in a final logistic regression
model that also contains the clinical predictors age, nodal status, tumor size, grade, estrogen receptor
status, and progesterone receptor status. For the derivation of the omics score, we applied a modelling
strategy that was able to handle the high-dimensional omics data. Specifically, we used a component-
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wise gradient boosting algorithm with linear base-learners (Friedman, 2001; Bühlmann & Yu, 2003;
Mayr et al., 2014) that automatically selected the most relevant predictors from the data. To avoid
overfitting, the number of boosting iterations, which is the main tuning parameter of the algorithm, was
optimized using 10-fold cross-validation. In our analysis, the optimal number of boosting iterations
was 15.
Figure 8 shows the RBP curve and the predictiveness curve for a meaningful final model, where the
omics score was computed using 15 boosting iterations, and for an overfitting final model, where the
omics score was computed using 300 boosting iterations. It can be seen that the RBP curve displays
the different predictive capacities of the models more clearly than the predictiveness curve, especially
for the overfitting model (black curves). This can be illustrated by deriving the PEV, TPR and FPR
measures from the RBP curves for training and test data for both models (see Figure 9). The first panel
(top left) of the figure refers to the overfitting model and shows an optimal RBP curve, having T PR = 1,
FPR = 0 and P̂EV = Ê1 − Ê0 = 1, which suggests a perfect fit on the training data. It can also be seen
that the overfitting model did not perform well when predicting the test data (see top right panel) as
opposed to the training data. For the test data, it is seen that the TPR is higher and the FPR is lower for
the meaningful model than for the overfitting model, suggesting that the meaningful model performed
better on the test data than the overfitting model.
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Figure 8: Predictiveness curves for training and test data of the overfitting and the meaningful model




































































































Figure 9: RBP curves for training and test data of the overfitting and the meaningful model using the
real data from Section 7. The dashed lines correspond to 95% bootstrap confidence bands.
8 Summary and Discussion
Because the prediction of binary outcomes has become increasingly important in biomedical research,
it is essential for practitioners to have reliable and unbiased measures of prediction accuracy. Re-
garding the derivation of summary measures, a remarkable number of strategies and easy-to-interpret
coefficients (such as AUC and PEV) are available.
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Equally important for practitioners is the availability of suitable graphical tools for visualizing pre-
diction accuracy. In this respect, the RBP curve is a natural choice, since it contains the full distribution
of the risks and several summary measures can be derived from it (see Section 5). It therefore reveals
the most relevant properties of a prediction model. Moreover, we demonstrated that the RBP curve
visualizes both discrimination and calibration and is therefore a suitable graphical tool for unbiased
marker comparisons. In contrast to strategies for the original predictiveness curve, the RBP curve
does not rely on (asymptotically valid) calibration tests and is therefore insensitive to power issues and
convergence problems.
The RBP curve is implemented in the R add-on package RBPcurve, which is publicly available
at http://cran.r-project.org (R Core Team, 2014). The package provides a user-friendly interface to
generate RBP curves and enables users to visualize the relationships between the RBP curve and the
performance measures discussed in Section 5.
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